Non-cytotoxic therapies for malignant gliomas

Journal of Neuro-Oncology

Volumn 58, Issue 1, 2002, Pages 57-69

  Basso, U ^a   Ermani, M ^a   Vastola, F ^a   Brandes, A A ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Angiogenesis; Brain tumors; Gene therapy; Immunotoxins; Non cytotoxic drugs; Review; Tyrosine kinase inhibitors

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; 5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; ALPHA INTERFERON; ALPHA2A INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; CARMUSTINE; ENDOSTATIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GEFITINIB; GOSSYPOL; IMATINIB; IMMUNOTOXIN; INTERLEUKIN 2; INTERLEUKIN 4 PLUS PSEUDOMONAS EXOTOXIN; ISOTRETINOIN; MARIMASTAT; METALLOPROTEINASE; ONCOLYTIC VIRUS; PHENYLACETIC ACID; PLACEBO; RECOMBINANT INTERFERON; SEMAXANIB; SURAMIN; TAMOXIFEN; TEMOZOLOMIDE; THALIDOMIDE; TRANSFERRIN CONJUGATE PLUS DIPHTHERIA TOXIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADOPTIVE IMMUNOTHERAPY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CHEILITIS; CLINICAL TRIAL; CYTOSTASIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG TARGETING; DRY SKIN; EDEMA; ENZYME INHIBITION; EXHAUSTION; FATIGUE; GASTROINTESTINAL SYMPTOM; GENE THERAPY; GLIOBLASTOMA; HEMIPARESIS; HUMAN; HYPOKALEMIA; LYMPHOCYTE TRANSFUSION; LYMPHOKINE ACTIVATED KILLER CELL; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; ONCOGENE; REVIEW; SEIZURE; SOMNOLENCE; TUMOR CELL; TUMOR SUPPRESSOR GENE; VACCINATION; XEROSTOMIA;

ANGIOGENESIS INHIBITORS; BRAIN NEOPLASMS; ENZYME INHIBITORS; GENE THERAPY; GLIOMA; HUMANS; IMMUNOTOXINS;

EID: 0036288505     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1015839111005     Document Type: Review

References (52)

1. High-dose chemotherapy with bone marrow rescue for high-grade gliomas in adults
2. Early chemotherapy and concurrent radio-chemotherapy in high grade glioma
3. New drugs in recurrent high grade gliomas
4. Molecular pathogenesis of malignant gliomas
5. In vitro and in vivo cytotoxicity of gossypol against central nervous system tumor cell lines
6. Gossypol treatment of recurrent adult malignant gliomas
7. A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer
8. Inhibition of proliferation and induction of differentiation in medulloblastoma- and astrocytoma-derived cell lines with phenylacetate
9. Growth inhibition, tumor maturation, and extended survival in experimental brain tumors in rats treated with phenylacetate
10. Phase II study of phenylacetate in patients with recurrent malignant glioma: A North American Brain Tumor Consortium report
11. Retinoic acid modulates RAR alpha and RAR beta receptors in human glioma cell lines
12. Retinoic acid receptor expression in human glioblastoma cell lines and modulation by exposure to all trans-retinoic acid of 9-cis-retinoic acid
13. Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid
14. Phase II evaluation of temozolomide and 13-cis Retinoic acid for the treatment of recurrent and progressive malignant gliomas
15. Structure-function analysis of signal and growth inhibition by carboxyamido-triazole, CAI
16. Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: Pharmacokinetics, clinical outcome, and comparison of formulations
17. Inhibitory effects of CAI in glioblastoma growth and invasion
18. Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumours
19. Intracranial inhibition of Platelet derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class
20. EGFR overexpression and radiation response in glioblastoma multiforme
21. Tyrosine kinase inhibitors-FD1839 (Iressa)
22. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor
23. Oral administration of the specific EGFR tyrosine kinase inhibitor, ZD1839 (IressaTM), is active against EGFR-overexpressing intracranial tumours
24. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas
25. Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme (GBM)
26. Antiangiogenic therapy in brain tumor models
27. A phase II study of temozolomide (Temodar) plus Marimastat for recurrent glioblastoma multiforme (GBM)
28. Human glioma immunobiology in vitro: Implications for immunogene therapy
29. Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma
30. Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma
31. Phase II trial with BCNU plus alpha interferon in patients with recurrent high-grade gliomas
32. A phase III study of radiation therapy plus carmustine with or without recombinant interferon-α in the treatment of patients with newly diagnosed high-grade glioma
33. High dose oral tamoxifen and subcutaneous interferon alpha-2a for recurrent glioma
34. Improved long term survival after intracavitary interleukin-2 lymphokine-activated killer cells for adults with recurrent malignant glioma
35. Systemic T cell adoptive immunotherapy of malignant gliomas
36. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration
37. Targeted toxin therapy for malignant astrocytoma
38. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors
39. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma
40. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy
41. Chemosensitivity of human malignant glioma: Modulation by p53 gene transfer
42. Progress in antiangiogenic gene therapy of cancer
43. Angiostatin gene transfer: Inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest
44. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells
45. Human malignant brain tumor response to herpes simplex thymidine kinase (HSVtk)/gancyclovir gene therapy
46. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses
47. Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration
48. Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: A pilot study in humans
49. Gene therapy of malignant gliomas: A pilot study of vaccination with irradiated autologous glioma and dendritic cells admixed with IL-4 transduced fibroblasts to elicit an immune response
50. Antisense oligodeoxynucleotide technology: Potential use for the treatment of malignant brain tumors
51. Intravenous administration of ONYX-015, a selective replicating adenovirus, induces antitumoral efficacy
52. Cancer. Has the smart bomb been defused?